ONK Therapeutics
15 articles about ONK Therapeutics
-
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
12/6/2023
NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA's FLEX-NK™ bispecific antibodies.
-
European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies
6/27/2023
ONK Therapeutics Ltd announced that the European Patent Office has granted its licensed patent covering CISH knockout in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells.
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
-
ONK Therapeutics Boosts Drug Development Experience and Expands US Presence with the Appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer
12/6/2022
ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer cell therapies to cure patients with cancer, announced the appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer.
-
ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma
8/29/2022
ONK Therapeutics announced the first in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy.
-
ONK Therapeutics announced Monday that its lead candidate showed potent anti-tumor activity both in-vivo and in-vitro versus multiple myeloma (MM)
-
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
-
Together, Intellia and ONK hope to develop, engineer and test new allogeneic CRISPR-edited NK cell therapies.
-
ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies
1/6/2022
ONK Therapeutics, an innovative NK cell therapy platform company, announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management.
-
ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.
-
USPTO Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies
9/9/2021
ONK Therapeutics Ltd, an innovative NK cell therapy company, announced that the US Patent and Trademark Office has granted its licensed patent that covers CISH knockout in NK cells, irrespective of the source of the NK cells, including, for example, human cord blood-derived and human induced pluripotent stem cell -derived cells.
-
ONK Therapeutics’ CSO Prof. M O’Dwyer and his Academic Group Present New Data Showing the Benefit of Knocking Out the Inhibitory Receptor CD96 on Human NK Cells in the Context of Multiple Myeloma at EHA 2021
6/11/2021
ONK Therapeutics Ltd. welcomes new data presented by John Daly from the academic lab of CSO, Prof. Michael O’Dwyer at the European Hematology Association (EHA) 2021 Virtual Congress illustrating the merit of knocking out the checkpoint inhibitory receptor for CD96 on NK cells in the context of MM.
-
ONK Therapeutics and Trinity College Dublin Collaborate in an Enterprise Ireland Funded Project to Optimize Metabolism of NK Cells for Improved Cancer Therapies
6/8/2021
ONK Therapeutics Ltd, an innovative natural killer cell therapy company, announced that it has been awarded an Innovation Partnership Programme grant by Enterprise Ireland to fund collaborative research at Trinity College Dublin, Ireland, led by Dr. David Finlay to optimize the metabolism and engineering of NK cells for improved cancer therapies.
-
ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout in NK Cells for the Treatment of Cancer, from Australia’s WEHI
5/27/2021
ONK Therapeutics Ltd, an innovative natural killer cell therapy company, announced that it has entered into an exclusive global patent license agreement with Australia’s Walter and Eliza Hall Institute of Medical Research providing rights to CISH KO in the field of NK cells for the treatment of cancer.
-
ONK Therapeutics Enters into a Research Agreement with NUI Galway to Support Optimization of its Dual-Targeted NK Cell Therapy against AML
5/17/2021
ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has entered into a research collaboration with the National University of Ireland, Galway (NUI Galway) which provides access to unique expertise in evaluating the cancer cell microenvironment in Acute Myeloid Leukaemia (AML) and targeting of AML stem cells in models mimicking the bone marrow microenvironment.